<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.2d1 20170631//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="article" dtd-version="1.2d1" specific-use="production" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">MEDRXIV</journal-id>
<journal-title-group>
<journal-title>medRxiv</journal-title>
<abbrev-journal-title abbrev-type="publisher">medRxiv</abbrev-journal-title>
</journal-title-group>
<publisher>
<publisher-name>Cold Spring Harbor Laboratory</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1101/2021.01.04.21249167</article-id>
<article-version>1.1</article-version>
<article-categories>
<subj-group subj-group-type="hwp-journal-coll">
<subject>Nursing</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>OPTIMIZING COVID-19 VACCINE USAGE</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-5444-721X</contrib-id>
<name><surname>Jara</surname><given-names>Carlos Poblete</given-names></name>
<xref ref-type="aff" rid="a1">1</xref>
<xref ref-type="aff" rid="a3">3</xref>
<xref ref-type="aff" rid="a4">4</xref>
<xref ref-type="corresp" rid="cor1">&#x002A;</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-4806-7218</contrib-id>
<name><surname>Velloso</surname><given-names>L&#x00ED;cio A.</given-names></name>
<xref ref-type="aff" rid="a2">2</xref>
<xref ref-type="aff" rid="a3">3</xref>
<xref ref-type="aff" rid="a4">4</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-7539-8477</contrib-id>
<name><surname>de Ara&#x00FA;jo</surname><given-names>Eliana Pereira</given-names></name>
<xref ref-type="aff" rid="a1">1</xref>
<xref ref-type="aff" rid="a3">3</xref>
<xref ref-type="aff" rid="a4">4</xref>
</contrib>
<aff id="a1"><label>1</label><institution>Faculty of Nursing</institution>, <country>Brazil</country></aff>
<aff id="a2"><label>2</label><institution>Faculty of Medical Sciences</institution>, <country>Brazil</country></aff>
<aff id="a3"><label>3</label><institution>Laboratory of Cell Signaling, Obesity and Comorbidities Research Center</institution>, <country>Brazil</country></aff>
<aff id="a4"><label>4</label><institution>University of Campinas</institution>, <country>Brazil</country></aff>
</contrib-group>
<author-notes>
<corresp id="cor1"><label>&#x002A;</label>Corresponding author: Carlos Poblete Jara, Faculty of Nursing, University of Campinas, UNICAMP, Tessalia Vieira de Camargo St, 126 - 13083-887 Campinas - SP - Brazil, E-mail: <email>blinkeado@gmail.com</email></corresp>
<fn fn-type="supported-by"><p>Financial support: Coordination of Improvement of Higher-Level Personnel of Brazil (CAPES)</p></fn>
</author-notes>
<pub-date pub-type="epub">
<year>2021</year>
</pub-date>
<elocation-id>2021.01.04.21249167</elocation-id>
<history>
<date date-type="received">
<day>04</day>
<month>1</month>
<year>2021</year>
</date>
<date date-type="rev-recd">
<day>04</day>
<month>1</month>
<year>2021</year>
</date>
<date date-type="accepted">
<day>05</day>
<month>1</month>
<year>2021</year>
</date>
</history>
<permissions>
<copyright-statement>&#x00A9; 2021, Posted by Cold Spring Harbor Laboratory</copyright-statement>
<copyright-year>2021</copyright-year>
<license license-type="creative-commons" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This pre-print is available under a Creative Commons License (Attribution 4.0 International), CC BY 4.0, as described at <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link></license-p></license>
</permissions>
<self-uri xlink:href="21249167.pdf" content-type="pdf" xlink:role="full-text"/>
<abstract>
<title>ABSTRACT</title>
<p>As the worldwide vaccination, it is imperative to minimize vaccine wastage by effectively using all doses available. Vaccine wastage can occur at multiple points during the vaccination process, but it is mainly because the device dead space and the filling process technique. However, there are no studies discussing the waste volume effect of COVID-19 vaccines in clinical practice. There is an increasing COVID-19 vaccine demand that we estimate up to several billion dual doses. The objective of this study was to assess the number of 0.3mL doses obtained from a multiple-dose vial using 1ml and 3ml syringes with different type of needles replicating the first COVID-19 vaccination protocol.</p><p>Our results suggest that it is possible to obtain six or seven doses from each vial instead five. We provide evidence to optimize between 20&#x0025; and 40&#x0025; additional vaccine doses per vial if the current 5-dose vials are used, making scarce supplies go further.</p><p>It is our duty, as researchers, to ensure the efficacy and efficiency of the worldwide COVID-19 vaccination process. However, if standard syringes-needles and technique are used, there may not be sufficient volume to draw extra doses from a single vial.</p>
</abstract>
<kwd-group kwd-group-type="author">
<title>Keywords</title>
<kwd>COVID-19</kwd>
<kwd>vaccine</kwd>
<kwd>sixth dose</kwd>
<kwd>optimization</kwd>
</kwd-group>
<counts>
<page-count count="12"/>
</counts>
</article-meta>
<notes>
<notes notes-type="competing-interest-statement">
<title>Competing Interest Statement</title><p>The authors have declared no competing interest.</p></notes>
<notes notes-type="financial-disclosure">
<title>Funding Statement</title><p>This study was supported, in part, by the Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior Brasil (CAPES) Finance Code 88882.434714 2019 01.</p></notes>
<notes notes-type="disclosures">
<title>Author Declarations</title><p>I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.</p><p>Yes</p><p>The details of the IRB/oversight body that provided approval or exemption for the research described are given below:</p><p>This study did not include human subject research, then, institutional review board authorization was not necessary</p><p>All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.</p><p>Yes</p><p>I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).</p><p>Yes</p><p>I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.</p><p>Yes</p></notes>
</notes>
</front>
<body>
<sec id="s1">
<title>INTRODUCTION</title>
<p>SARS-CoV-2, the pathogenic agent of COVID-19, has had devastating consequences globally. Worldwide, COVID-19 overwhelm lifestyle, macroeconomic and threatens to affect billion human lives <sup><xref ref-type="bibr" rid="c1">1</xref>-<xref ref-type="bibr" rid="c3">3</xref></sup>.</p>
<p>The COVID-19 vaccination campaigns are being conducted to interrupt SARS-CoV-2 transmission and has shown efficacy in preventing COVID-19 illness<sup><xref ref-type="bibr" rid="c4">4</xref>-<xref ref-type="bibr" rid="c9">9</xref></sup>. Vaccines are needed to prevent COVID-19 and to protect people who are at high risk for complications <sup><xref ref-type="bibr" rid="c4">4</xref></sup>. Currently, there are only few companies producing COVID-19 vaccines, and optimization of usage could expand considerably the number of people immunized. There are currently not many manufacturers globally of COVID-19 vaccines to provide a short period proper number of vaccines for the world population. In this way, it is imperative to avoid vaccine wastages by effectively use all doses available. Vaccine wastage can occur at multiple points during the preparation, filling, and inoculation processes, but it is mainly because the device dead space and filling process technique<sup><xref ref-type="bibr" rid="c10">10</xref>-<xref ref-type="bibr" rid="c15">15</xref></sup>:</p>
<p>One vital device is an appropriate syringe-needle system for delivering the vaccine. The association between needle-syringe system and waste were previously reported<sup><xref ref-type="bibr" rid="c10">10</xref>,<xref ref-type="bibr" rid="c16">16</xref>,<xref ref-type="bibr" rid="c17">17</xref></sup>. However, there are no publications discussing the waste volume effect of COVID-19 vaccines in clinical practice.</p>
<p>With the possibility of billions to be infected and the limited vaccine supply, it is essential that the syringe-needle system used waste as little as possible and consequently allow for a higher number of people vaccinated<sup><xref ref-type="bibr" rid="c17">17</xref></sup>.</p>
<p>Here, we assessed the number of doses draw from a multiple-dose vial, simulating the first COVID-19 vaccination protocol. Our goal was to optimize the COVID-19 vaccine wastage. We showed different syringe-needle system to use and we explored a no dead-volume approach to draw a seventh dose.</p>
</sec>
<sec id="s2">
<title>RESULTS</title>
<sec id="s2a">
<title>Syringe &#x2013; needle system wastage</title>
<p>We simulated the vaccination process pre-loading 0.45mL of saline diluted with 1.8 mL of 0.9&#x0025; Sodium Chloride (<xref rid="fig1" ref-type="fig">Figure 1a</xref>). We found the mean dead-volume of the syringe &#x2013; needle system ranged from 40 &#x03BC;L to 560 &#x03BC;L per vial (<xref rid="tbl1" ref-type="table">Table 1</xref>). The lower dead-volume was found in the no dead-volume group (<xref rid="fig1" ref-type="fig">Figure 1b, e</xref>) and the higher waste volume in the 3 ml syringe-23Gx1 needle group (<xref rid="fig1" ref-type="fig">Figure 1c, e</xref>). Also, we found the aspiration varied between needle Gauge and syringe system and ranged from 1.69 mL to 2.21 mL per vial (<xref rid="tbl1" ref-type="table">Table 1</xref>). Specifically, our results showed that the 3 mL syringe attached to 27Gx1/2 needle, increased the total volume recovered from the multiple-dose vial compared to the 3 mL syringe-23Gx1 needle system (<xref rid="tbl1" ref-type="table">Table 1</xref>, Figure d).</p>
<table-wrap id="tbl1" orientation="portrait" position="float">
<label>Table 1.</label>
<caption><p>Recovered: mean value of fluid withdraws from each vial. Dead volume: mean value of the difference between the 2.25 mL initial load and the recovered fluid from each vial. Doses: mean value of number of doses from each vial. &#x0025; &#x003E; 5 doses, &#x0025; &#x003E; 6 doses, and &#x0025; &#x003E; 7 doses: percentage of times reaching the pointed value. (a): no dead-volume approach. Mean values<underline>&#x002B;</underline> Standard deviation. All experiments in quadruplicate.</p></caption>
<graphic xlink:href="21249167v1_tbl1.tif"/>
</table-wrap>
<fig id="fig1" position="float" fig-type="figure">
<label>Figure 1.</label>
<caption><title>Experimental design and syringe-needle comparison.</title>
<p>Schematic of testing process (a); Filled syringe-needle system with and without dead-volume (b). Total recovery of 0.9&#x0025; Sodium Chloride from a 2.25 mL filled vial using different syringe-needle systems (c); Total dead-volume of 0.9&#x0025; Sodium Chloride from a 2.25 mL filled vial using different syringe-needle systems (d); Percentage of doses recovered from a 2.25 mL filled vial using different syringe-needle systems (e).</p></caption>
<graphic xlink:href="21249167v1_fig1.tif"/>
</fig>
<p>Next, we showed that is possible to use every full dose, the sixth, or even a seventh dose from a multiple-dose vial. We obtained a sixth dose from each vial 50&#x0025; of the times using a 3ml-27Gx1/2 needle system for the dose extraction (<xref rid="tbl1" ref-type="table">Table 1</xref>, <xref rid="fig1" ref-type="fig">Fig. 1f</xref>).</p>
<p>Then, after we had stablished 27Gx1 needle is the best option for the doses withdraw, we compared 3mL to 1mL syringes. We identified that 1mL syringe constantly improved the total volume recovered from the multiple-dose vial compared to 3mL (<xref rid="fig1" ref-type="fig">Figure 1d</xref>). Also, 1 mL syringe decreased the dead-volume compared to 3 mL syringe (<xref rid="fig1" ref-type="fig">Figure 1e</xref>). Moreover, independently of the needle Gauge, 1 mL syringe constantly recovered six doses from the multiple-dose vial compared to 3mL (<xref rid="fig1" ref-type="fig">Figure 1f</xref>). On the other hand, there is no differences in the number of doses draw, total volume, or dead volume collected by using 23G or 27G needles attached to a 1mL syringe (<xref rid="fig1" ref-type="fig">Fig. 1d-f</xref>).</p>
<p>Finally, we obtained the seventh dose from a multiple-dose vial using a no dead-volume approach (<xref rid="fig1" ref-type="fig">Figure 1b, f</xref>).</p>
<p>The data suggest that switching to 1 mL-23G system or to a no dead-volume approach from any of the others tested would provide between 20 and 40&#x0025; additional vaccine doses per vial if the current 5-dose vials are used (<xref rid="tbl1" ref-type="table">Table 1</xref>)</p>
</sec>
</sec>
<sec id="s3">
<title>DISCUSSION</title>
<p>Now, it is our duty, as physicians and nurses, to ensure the efficacy and efficiency of the worldwide COVID-19 vaccination process. However, if standard syringes-needles and technique are used, there may not be sufficient volume to draw extra doses from a single vial. Indeed, we learned this important lesson from the Influenza pandemic<sup><xref ref-type="bibr" rid="c10">10</xref>,<xref ref-type="bibr" rid="c17">17</xref></sup>.</p>
<p>If we only extracted five doses instead of six, as described on the vial label of the first FDA COVID-19 vaccine approved, we could lose up to 1.4 billion doses. In this way, we could waste not only doses, but priceless time, extending the vaccination campaign, billions of dollars, and most importantly, human lives. But not only the high dead-volume inside the syringes and needles could be a problem. In the vaccination practice, and according to the manufacturer <sup><xref ref-type="bibr" rid="c18">18</xref></sup>, any further remaining product inside the vial should not be pooled with other vial residue to obtain extra doses.</p>
<p>There is an increasing COVID-19 vaccine demand that we estimate up to 14 billion dual doses. We are on time to advise the public health authorities to make the best possible decision regarding to the syringe systems to face the COVID-19 vaccination process. Remains pending for future studies to test different COVID-19 vaccines with low dead-volume syringe to evaluate the number of doses obtained as previously described <sup><xref ref-type="bibr" rid="c17">17</xref></sup>.</p>
</sec>
<sec id="s4">
<title>METHODS</title>
<p>This study did not include human subject research, then, institutional review board authorization was not necessary <sup><xref ref-type="bibr" rid="c16">16</xref></sup>. We used 0.9&#x0025; Sodium Chloride, two types of needles and two types of high dead-volume syringes for effectiveness analysis. All experiments in quadruplicate.</p>
<sec id="s4a">
<title>Dose Preparation and dilution</title>
<p>For the procedure involved 1 mL and 3 mL syringes (Nipro syringe) we used a 27 Gauge &#x00BD; &#x201C;needle (0.4 x 13mm) and a 23 Gauge 1&#x201D; needle (0.6mm x 25mm), all systems used with luer lock.</p>
<p>Four different syringe-needle system were tested (<xref rid="fig1" ref-type="fig">Figure 1a</xref>): 1 mL syringe attached to 23- or 27-Gauge needle and 3 mL syringe attached to 23- or 27-Gauge needle (23G or 27G respectively). To quantify the number of microliters recovered from the vials, we calculated the number of syringes filled in with 0.3mL of solution times 0.3 plus the last dose extracted using a 1 mL syringe.</p>
<p>Clean and dry 5 mL-vials capacity (FluQuadri, Sanofi Medley) were used for all experiments. 0.45 mL of 0.9&#x0025; Sodium Chloride (Baxter, for IV Infusions in Viaflex Container) was loaded in one vial using a 1 mL syringe &#x2212;23G needle system representing the <italic>undiluted vial</italic>. 1.8 mL 0.9&#x0025; Sodium Chloride was diluted in the 0.45 mL &#x201C;undiluted vial&#x201D; using a 3 mL syringe-23G needle system. We made sure to remove all air prior to drawing up. We used new needles and syringes in each draw, mimicking a vaccination procedure.</p>
</sec>
<sec id="s4b">
<title>No dead-volume approach</title>
<p>We considered syringe-needle dead space was the volume of residual fluid that remains within the syringe-needle system after the plunger is fully depressed during inoculation<sup><xref ref-type="bibr" rid="c11">11</xref>,<xref ref-type="bibr" rid="c16">16</xref></sup>. A different technique for the no dead-volume approach was used by considering 0.0 mL as the starting point and filled in until 0.3 milliliters (<xref rid="fig1" ref-type="fig">Figure 1b</xref> left). After 0.3 mL reached, an extra 0.1-0.2 mL air volume was added to force all fluid draw out the syringe-needle system. The air volume was positioned in the plunger side of the syringe (<xref rid="fig1" ref-type="fig">Figure 1b</xref> right).</p>
</sec>
<sec id="s4c">
<title>Statistical Analysis</title>
<p>The data are presented as the mean &#x00B1; S.D. We used one-way ANOVA to compare more than two groups. P &#x003C; 0.05 was considered statistically significant. Tukey&#x2019;s test for multiple comparison. We used GraphPad Prism 9 for Windows to perform statistical analysis. Graphical representation were created with <ext-link ext-link-type="uri" xlink:href="http://BioRender.com">BioRender.com</ext-link>.</p>
</sec>
</sec>
</body>
<back>
<sec sec-type="data-availability">
<title>Data Availability</title>
<p>All data is in table 1</p>
</sec>
<ref-list>
<title>Bibliography</title>
<ref id="c1"><label>1.</label><mixed-citation publication-type="journal"><string-name><surname>Kassa</surname> <given-names>MD</given-names></string-name>, <string-name><surname>Grace</surname> <given-names>JM</given-names></string-name>. <article-title>Race against death or starvation? COVID-19 and its impact on African populations</article-title>. <source>Public Health Rev</source> <year>2020</year>;<volume>41</volume>(<issue>1</issue>):<fpage>30</fpage>. (In eng). DOI: <pub-id pub-id-type="doi">10.1186/s40985-020-00139-0</pub-id>.</mixed-citation></ref>
<ref id="c2"><label>2.</label><mixed-citation publication-type="other"><string-name><surname>Graso</surname> <given-names>M</given-names></string-name>, <string-name><surname>Chen</surname> <given-names>FX</given-names></string-name>, <string-name><surname>Reynolds</surname> <given-names>T.</given-names></string-name> <article-title>Moralization of Covid-19 health response: Asymmetry in tolerance for human costs</article-title>. <source>J Exp Soc Psychol: &#x00A9; 2020 Elsevier Inc. All rights reserved</source>.; <year>2020</year>:<fpage>104084</fpage>.</mixed-citation></ref>
<ref id="c3"><label>3.</label><mixed-citation publication-type="journal"><string-name><surname>Mei</surname> <given-names>Q</given-names></string-name>, <string-name><surname>Wang</surname> <given-names>AY</given-names></string-name>, <string-name><surname>Bryant</surname> <given-names>A</given-names></string-name>, <etal>et al.</etal> <article-title>Development and validation of prognostic model for predicting mortality of COVID-19 patients in Wuhan, China</article-title>. <source>Scientific Reports</source> <year>2020</year>;<volume>10</volume>(<issue>1</issue>):<fpage>22451</fpage>. DOI: <pub-id pub-id-type="doi">10.1038/s41598-020-78870-6</pub-id>.</mixed-citation></ref>
<ref id="c4"><label>4.</label><mixed-citation publication-type="other"><string-name><surname>Baden</surname> <given-names>LR</given-names></string-name>, <string-name><surname>El Sahly</surname> <given-names>HM</given-names></string-name>, <string-name><surname>Essink</surname> <given-names>B</given-names></string-name>, <etal>et al.</etal> <article-title>Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine</article-title>. <source>New England Journal of Medicine</source> <year>2020</year>. DOI: <pub-id pub-id-type="doi">10.1056/NEJMoa2035389</pub-id>.</mixed-citation></ref>
<ref id="c5"><label>5.</label><mixed-citation publication-type="other"><string-name><surname>Widge</surname> <given-names>AT</given-names></string-name>, <string-name><surname>Rouphael</surname> <given-names>NG</given-names></string-name>, <string-name><surname>Jackson</surname> <given-names>LA</given-names></string-name>, <etal>et al.</etal> <article-title>Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination</article-title>. <source>New England Journal of Medicine</source> <year>2020</year>. DOI: <pub-id pub-id-type="doi">10.1056/NEJMc2032195</pub-id>.</mixed-citation></ref>
<ref id="c6"><label>6.</label><mixed-citation publication-type="journal"><string-name><surname>Keech</surname> <given-names>C</given-names></string-name>, <string-name><surname>Albert</surname> <given-names>G</given-names></string-name>, <string-name><surname>Cho</surname> <given-names>I</given-names></string-name>, <etal>et al.</etal> <article-title>Phase 1&#x2013;2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine</article-title>. <source>New England Journal of Medicine</source> <year>2020</year>;<volume>383</volume>(<issue>24</issue>):<fpage>2320</fpage>&#x2013;<lpage>2332</lpage>. DOI: <pub-id pub-id-type="doi">10.1056/NEJMoa2026920</pub-id>.</mixed-citation></ref>
<ref id="c7"><label>7.</label><mixed-citation publication-type="journal"><string-name><surname>Walsh</surname> <given-names>EE</given-names></string-name>, <string-name><surname>Frenck</surname> <given-names>RW</given-names></string-name>, <string-name><surname>Falsey</surname> <given-names>AR</given-names></string-name>, <etal>et al.</etal> <article-title>Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates</article-title>. <source>New England Journal of Medicine</source> <year>2020</year>;<volume>383</volume>(<issue>25</issue>):<fpage>2439</fpage>&#x2013;<lpage>2450</lpage>. DOI: <pub-id pub-id-type="doi">10.1056/NEJMoa2027906</pub-id>.</mixed-citation></ref>
<ref id="c8"><label>8.</label><mixed-citation publication-type="journal"><string-name><surname>Polack</surname> <given-names>FP</given-names></string-name>, <string-name><surname>Thomas</surname> <given-names>SJ</given-names></string-name>, <string-name><surname>Kitchin</surname> <given-names>N</given-names></string-name>, <etal>et al.</etal> <article-title>Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine</article-title>. <source>New England Journal of Medicine</source> <year>2020</year>;<volume>383</volume>(<issue>27</issue>):<fpage>2603</fpage>&#x2013;<lpage>2615</lpage>. DOI: <pub-id pub-id-type="doi">10.1056/NEJMoa2034577</pub-id>.</mixed-citation></ref>
<ref id="c9"><label>9.</label><mixed-citation publication-type="journal"><string-name><surname>Anderson</surname> <given-names>EJ</given-names></string-name>, <string-name><surname>Rouphael</surname> <given-names>NG</given-names></string-name>, <string-name><surname>Widge</surname> <given-names>AT</given-names></string-name>, <etal>et al.</etal> <article-title>Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults</article-title>. <source>New England Journal of Medicine</source> <year>2020</year>;<volume>383</volume>(<issue>25</issue>):<fpage>2427</fpage>&#x2013;<lpage>2438</lpage>. DOI: <pub-id pub-id-type="doi">10.1056/NEJMoa2028436</pub-id>.</mixed-citation></ref>
<ref id="c10"><label>10.</label><mixed-citation publication-type="journal"><string-name><surname>Jarrahian</surname> <given-names>C</given-names></string-name>, <string-name><surname>Rein-Weston</surname> <given-names>A</given-names></string-name>, <string-name><surname>Saxon</surname> <given-names>G</given-names></string-name>, <etal>et al.</etal> <article-title>Vial usage, device dead space, vaccine wastage, and dose accuracy of intradermal delivery devices for inactivated poliovirus vaccine (IPV)</article-title>. <source>Vaccine</source> <year>2017</year>;<volume>35</volume>(<issue>14</issue>):<fpage>1789</fpage>-<lpage>1796</lpage>. (In eng). DOI: <pub-id pub-id-type="doi">10.1016/j.vaccine.2016.11.098</pub-id>.</mixed-citation></ref>
<ref id="c11"><label>11.</label><mixed-citation publication-type="journal"><string-name><surname>Oramasionwu</surname> <given-names>CU</given-names></string-name>, <string-name><surname>Cole</surname> <given-names>AL</given-names></string-name>, <string-name><surname>Dixon</surname> <given-names>MS</given-names></string-name>, <etal>et al.</etal> <article-title>Estimated Cost of Injectable Medication Waste Attributable to Syringe Dead Space</article-title>. <source>JAMA Intern Med</source> <year>2016</year>;<volume>176</volume>(<issue>7</issue>):<fpage>1025</fpage>-<lpage>7</lpage>. (In eng). DOI: <pub-id pub-id-type="doi">10.1001/jamainternmed.2016.2301</pub-id>.</mixed-citation></ref>
<ref id="c12"><label>12.</label><mixed-citation publication-type="journal"><string-name><surname>Bach</surname> <given-names>PB</given-names></string-name>, <string-name><surname>Conti</surname> <given-names>RM</given-names></string-name>, <string-name><surname>Muller</surname> <given-names>RJ</given-names></string-name>, <string-name><surname>Schnorr</surname> <given-names>GC</given-names></string-name>, <string-name><surname>Saltz</surname> <given-names>LB</given-names></string-name>. <article-title>Overspending driven by oversized single dose vials of cancer drugs</article-title>. <source>Bmj</source> <year>2016</year>;<volume>352</volume>:<fpage>i788.</fpage> (In eng). DOI: <pub-id pub-id-type="doi">10.1136/bmj.i788</pub-id>.</mixed-citation></ref>
<ref id="c13"><label>13.</label><mixed-citation publication-type="journal"><string-name><surname>Zule</surname> <given-names>WA</given-names></string-name>, <string-name><surname>Ticknor-Stellato</surname> <given-names>KM</given-names></string-name>, <string-name><surname>Desmond</surname> <given-names>DP</given-names></string-name>, <string-name><surname>Vogtsberger</surname> <given-names>KN</given-names></string-name>. <article-title>Evaluation of needle and syringe combinations</article-title>. <source>J Acquir Immune Defic Syndr Hum Retrovirol</source> <year>1997</year>;<volume>14</volume>(<issue>3</issue>):<fpage>294</fpage>-<lpage>5</lpage>. (In eng). DOI: <pub-id pub-id-type="doi">10.1097/00042560-199703010-00015</pub-id>.</mixed-citation></ref>
<ref id="c14"><label>14.</label><mixed-citation publication-type="journal"><string-name><surname>Berne</surname> <given-names>C</given-names></string-name>, <string-name><surname>Agen&#x00E4;s</surname> <given-names>I</given-names></string-name>, <string-name><surname>Eriksson</surname> <given-names>G</given-names></string-name>, <string-name><surname>Wibell</surname> <given-names>L.</given-names></string-name> <article-title>Insulin wastage in ambulant practice</article-title>. <source>Diabetes Care</source> <year>1984</year>;<volume>7</volume>(<issue>4</issue>):<fpage>343</fpage>-<lpage>6</lpage>. (In eng). DOI: <pub-id pub-id-type="doi">10.2337/diacare.7.4.343</pub-id>.</mixed-citation></ref>
<ref id="c15"><label>15.</label><mixed-citation publication-type="journal"><string-name><surname>Shainfeld</surname> <given-names>FJ</given-names></string-name>. <article-title>Errors in insulin doses due to the design of insulin syringes</article-title>. <source>Pediatrics</source> <year>1975</year>;<volume>56</volume>(<issue>2</issue>):<fpage>302</fpage>-<lpage>3</lpage>. (In eng).</mixed-citation></ref>
<ref id="c16"><label>16.</label><mixed-citation publication-type="journal"><string-name><surname>Golan</surname> <given-names>S</given-names></string-name>, <string-name><surname>Pena</surname> <given-names>J</given-names></string-name>, <string-name><surname>Moore</surname> <given-names>J</given-names></string-name>, <string-name><surname>Tandalam</surname> <given-names>S</given-names></string-name>, <string-name><surname>Lelli</surname> <given-names>G.</given-names></string-name> <article-title>The Association between Needle Size and Waste Product and Its Effect on Cost-Effectiveness of Botulinum Toxin Injections?</article-title> <source>Facial Plast Surg</source> <year>2020</year>;<volume>36</volume>(<issue>4</issue>):<fpage>484</fpage>-<lpage>486</lpage>. (In eng). DOI: <pub-id pub-id-type="doi">10.1055/s-0040-1713793</pub-id>.</mixed-citation></ref>
<ref id="c17"><label>17.</label><mixed-citation publication-type="journal"><string-name><surname>Strauss</surname> <given-names>K</given-names></string-name>, <string-name><surname>van Zundert</surname> <given-names>A</given-names></string-name>, <string-name><surname>Frid</surname> <given-names>A</given-names></string-name>, <string-name><surname>Costigliola</surname> <given-names>V.</given-names></string-name> <article-title>Pandemic influenza preparedness: the critical role of the syringe</article-title>. <source>Vaccine</source> <year>2006</year>;<volume>24</volume>(<issue>22</issue>):<fpage>4874</fpage>-<lpage>82</lpage>. (In eng). DOI: <pub-id pub-id-type="doi">10.1016/j.vaccine.2006.02.056</pub-id>.</mixed-citation></ref>
<ref id="c18"><label>18.</label><mixed-citation publication-type="other"><collab>Pfizer-BioNTech</collab>. <source>FACT SHEET FOR HEALTHCARE PROVIDERS ADMINISTERING VACCINE (VACCINATION PROVIDERS). In: Pfizer-BioNTech, ed. USA</source> <year>2020</year>.</mixed-citation></ref>
</ref-list>
<ack>
<title>ACKNOWLEDGEMENTS</title>
<p>The authors are grateful to Gladys Paredes Ulloa, Carlos Castro, Patricia Nilo, Jocelyn Araya, CESFAM Sarmiento and Ilustre Municipalidad de Curico. for technical assistance and financial support. This study was supported, in part, by the Coordena&#x00E7;&#x00E3;o de Aperfei&#x00E7;oamento de Pessoal de N&#x00ED;vel Superior &#x2013; Brasil (CAPES) &#x2013; Finance Code 88882.434714/2019&#x2013;01.</p>
</ack>
<sec id="s5">
<title>CONFLICTS OF INTEREST</title>
<p>No conflicts of interest</p>
</sec>
<sec id="s6">
<title>AUTHOR CONTRIBUTIONS</title>
<p>CPJ: Conceptualization, Formal analysis, Methodology, Investigation, Writing - Original Draft, Writing - Review &#x0026; Editing</p>
<p>LAV: Formal analysis, Writing - Review &#x0026; Editing, Supervision</p>
<p>EPA: Conceptualization, Methodology, Formal analysis, Resources, Writing - Original Draft, Writing - Review &#x0026; Editing, Supervision</p>
</sec>
</back>
</article>